



ASCO QOPI certification, why, when and for whom. Medisprof Cluj Romania experience

Anghel Adrian Udrea

Medisprof SRL, Romania

Abstract

Evolution Background: QOPI® is a practice-based system of quality self-assessment operated by ASCO (American Society of Clinical Oncology) with the goals of improving cancer care and prevention. It promotes excellence in cancer care by helping practices to create a culture of self-examination and improvement. Medisprof cancer centre was seeking from the beginning ASCO standards as a proof of interest in quality of the services offered to the patients.

Methods: The process employed for the certification includes measurements, feedback, and improvement tools for oncology practices. Motivation of the team was one of the most important tasks for the administration in order to achieve these goals.

Results: Between 2016 -2018 we had to adapt our procedures and policies in order to align them to QOPI ® requirements. This process included training of the professionals working at the Centre: pharmacists, nurses, secretaries, psychologists and doctors. The working team included a data manager that built an electronic medical record in Romanian for the auditors to follow the progress made to achieve the goals. Written information given to the patients was now more comprehensive, also for those following oral medications at home. Laminar flow hood systems and equipment for internal pharmacy as well as for treatment rooms was updated.

Conclusions: Medisprof Cancer Centre was awarded in August 2018 with QOPI ® ASCO certification. More responsibility of the team, in their everyday activities, was maybe the most important achievement of the process. Next steps will be ACRO (American college of Radiation Oncology) certification for Radiotherapy department and closely working with ASCO QTP (Quality training program) team in order to further improve the quality of our services in all departments.

Biography

Anghel Adrian Udrea, as a PI, has proven track record of professionalism, conducting over 80 successful clinical trials, a great number being conducted at Medisprof. During the past eight years, Medisprof has become a landmark as a Romanian research site and is continuing to grow thanks to our qualified research team. Being Chief Medical Officer has shown me the difficulties of leadership but also the perspective of future achievements with the proper team. As a recognition of our efforts, in August 10, 2018 we received the QOPI certification from ASCO.



Publications

1. Anghel Adrian Udrea, Tae Won Kim, Anneli Elme, Joon Oh Park (2018) Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, Sep 2018
2. Anghel Adrian Udrea, T. Sarosiek, M. Shenker, J.A. Ajani (2017) 698PA dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB. *Annals of Oncology* 28(suppl_5) Sep 2017
3. Anghel Adrian Udrea, Anneli Elme, Tae Won Kim, Joon Oh Park (2017) Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC). *Journal of Clinical Oncology* 35(15_suppl):3561-3561
4. Anghel Adrian Udrea, Jérôme Fayette, Lori Wirth, Cristina Oprean (2016) Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN study). *Frontiers in Oncology* 6(66) October 2016
5. Anghel Adrian Udrea, Anneli Elme, Tae Won Kim, Joon Oh Park, Zvonko Kusic, Sun Kim, Jun Dong, Nebojsa Manojlovic (2016) A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. *British Journal of Cancer* volume 115, pages1206–1214(2016)

[17th International Conference on Oncology Nursing and Cancer Care](#)

Edinburgh, Scotland | March 04-5, 2020

Citation: Anghel Adrian Udrea, *ASCO QOPI certification, why, when and for whom. Medisprof Cluj Romania experience*, *Cancer Nursing* 2020, 17th International Conference on Oncology Nursing and Cancer Care March 04-05, 2020 | Edinburgh, Scotland, 2471-2671-6:3-02